
The START Center for Cancer Research (“START”) is the world’s largest early phase site network, fully dedicated to oncology clinical research. Throughout our history, START has provided hope to cancer patients in global community practices by offering "Hope Through Access” to cutting edge trials throughout the United States and Europe.
The START Center for Cancer Research is seeking a Director, Investigational Drug Section who is responsible for overseeing all components of IDS operations at the assigned site. Additionally, the director should fulfill all existing clinical pharmacist job duties. This includes all facets of medication order verification, dispensing and documentation process for investigational drugs, conventional chemotherapy and supportive care medications provided by the IDS. The pharmacist may be involved in the provision of pharmaceutical care including assisting with patient interviews, maintenance of current medication lists, providing patient medication education, providing drug information to the healthcare team and patients. The pharmacist will practice with a high degree of autonomy, guided by IDS SOPs and quality assurance verification guidelines. This role is responsible for the daily supervision of staff assigned to medication preparation, dispensing, and operation of the IDS in accordance with all applicable rules and regulations. The director will serve as a direct supervisor to all site-specific pharmacy team members including other pharmacists and pharmacy technicians.
Schedule Monday - Friday 8 a.m. - 5 p.m
Location: START Richmond / Norfolk / South Carolina must be able to travel up to 25% to sites intermittently
Essential Responsibilities
Required Education and Experience:
Preferred Education and Experience:
Physical & Travel Requirements:
Best-in-Class Benefits and Perks
We value our employees’ time and efforts. Our commitment to your success is enhanced by a competitive compensation, depending on experience, and an extensive benefits package including:
More about The START Center for Cancer Research
Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a thousand early-phase clinical trials, including for 43 therapies that were approved by the FDA. START represents the world’s largest roster of Principal Investigators (PIs) across its eight clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world.
Learn more at STARTresearch.com
Ready to be part of a team changing the future of cancer treatment?
Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.
We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.

Deeply rooted in community oncology centers globally, the START Center for Cancer Research ("START") provides patients with access to specialized Phase 1 clinical trials for novel anti-cancer agents. With research sites in the United States and in Spain, Portugal, and Ireland, START’s clinical trial sites have conducted more than 1,500 early phase clinical trials, including for 45 therapies that have gained FDA/EMA approval. Founded in Texas in 2007, START today boasts 30+ Principal Investigators (PIs) across its worldwide clinical trial sites. With over 100,000+ square feet of world-class research facilities, START offers patients comprehensive treatment plans that include multi-specialty services, genetic profiling of tumors, targeted therapies, state-of-the-art treatment technology, and advanced access to clinical research options. START is committed to accelerating passage from trials to treatments, and to delivering hope to patients, families, and physicians around the world.